BioLife Solutions (NASDAQ:BLFS) Director Amy Duross Sells 477 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) Director Amy Duross sold 477 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $24.50, for a total transaction of $11,686.50. Following the sale, the director directly owned 30,210 shares of the company’s stock, valued at approximately $740,145. The trade was a 1.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Amy Duross also recently made the following trade(s):

• On Friday, November 21st, Amy Duross sold 1,000 shares of BioLife Solutions stock. The stock was sold at an average price of $26.00, for a total value of $26,000.00.
• On Thursday, November 20th, Amy Duross sold 4,523 shares of BioLife Solutions stock. The stock was sold at an average price of $24.51, for a total value of $110,858.73.

BioLife Solutions Stock Up 9.6%

BLFS traded up $2.33 during trading on Friday, hitting $26.53. The company’s stock had a trading volume of 540,117 shares, compared to its average volume of 456,202. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -221.06 and a beta of 1.97. The firm’s 50 day moving average price is $26.38 and its two-hundred day moving average price is $24.12. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.62.

Wall Street Analysts Forecast Growth

BLFS has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright reiterated a “buy” rating and set a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Finally, Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.20.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. CIBC Bancorp USA Inc. acquired a new stake in shares of BioLife Solutions during the third quarter worth $1,064,000. PharVision Advisers LLC acquired a new position in BioLife Solutions in the third quarter valued at about $316,000. Quarry LP boosted its holdings in BioLife Solutions by 50.9% during the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 713 shares during the last quarter. Millennium Management LLC grew its position in shares of BioLife Solutions by 2.9% during the 3rd quarter. Millennium Management LLC now owns 27,698 shares of the medical equipment provider’s stock worth $707,000 after buying an additional 783 shares during the period. Finally, Zacks Investment Management grew its position in shares of BioLife Solutions by 6.5% during the 3rd quarter. Zacks Investment Management now owns 69,230 shares of the medical equipment provider’s stock worth $1,766,000 after buying an additional 4,246 shares during the period. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.